Cabaletta Bio (CABA)
NASDAQ:CABA
US Market

Cabaletta Bio (CABA) Stock Price & Analysis

225 Followers

CABA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.59 - $12.82
Previous Close$12.37
Volume376.74K
Average Volume (3M)877.32K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$85.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-7.0
Beta2.98
Next EarningsMar 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.78
Shares Outstanding29,140,810
R-Squared0.10
Standard Deviation0.46
10 Day Avg. Volume778,073
30 Day Avg. Volume877,317
Price to Book (P/B)4.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-9.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside-0.16% Downside
Rating ConsensusStrong Buy
Alpha0.06
Number of Analyst Covering5


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CABA FAQ

What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $0.59 and its highest was $12.82 in the past 12 months.
    What is Cabaletta Bio’s market cap?
    Currently, no data Available
    When is Cabaletta Bio’s upcoming earnings report date?
    Cabaletta Bio’s upcoming earnings report date is Mar 15, 2023 which is in 35 days.
      How were Cabaletta Bio’s earnings last quarter?
      Cabaletta Bio released its earnings results on Nov 10, 2022. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.06.
        Is Cabaletta Bio overvalued?
        According to Wall Street analysts Cabaletta Bio’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Cabaletta Bio pay dividends?
          Cabaletta Bio does not currently pay dividends.
          What is Cabaletta Bio’s EPS estimate?
          Cabaletta Bio’s EPS estimate is -$0.44.
            How many shares outstanding does Cabaletta Bio have?
            Cabaletta Bio has 29,140,810 shares outstanding.
              What happened to Cabaletta Bio’s price movement after its last earnings report?
              Cabaletta Bio reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went up 4.639%.
                Which hedge fund is a major shareholder of Cabaletta Bio?
                Among the largest hedge funds holding Cabaletta Bio’s share is Deerfield Management Company, LP. It holds Cabaletta Bio’s shares valued at 302K.

                  ---

                  Cabaletta Bio Stock Smart Score

                  10
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  317.90%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -50.54%
                  Trailing 12-Months
                  Asset Growth
                  -25.25%
                  Trailing 12-Months
                  The Cabaletta Bio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Cabaletta Bio

                  Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Medicinova
                  Cel-Sci
                  Rigel
                  Inmune Bio
                  Sesen Bio

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis